MEI Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

MEI Pharma şirketinin toplam hissedar öz sermayesi $24.9M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $27.8M ve $2.9M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$26.91m
Eşitlik	US$24.88m
Toplam yükümlülükler	US$2.87m
Toplam varlıklar	US$27.75m

Son finansal sağlık güncellemeleri

We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

May 18

We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate

Nov 04

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Feb 17

Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)

Dec 30

Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)

Nov 19

We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

May 18

Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022

Mar 26

Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts

Feb 12

MEI Pharma: Another PI3K Delta Progressing To The FDA

Feb 01

Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates

Dec 02

The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their Holding

Feb 25

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Feb 11

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MEIP 'nin kısa vadeli varlıkları ( $27.7M ) kısa vadeli yükümlülüklerini ( $2.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: MEIP un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MEIP borçsuzdur.

Borcun Azaltılması: MEIP son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MEIP şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: MEIP un, serbest nakit akışı her yıl % 18.9 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

MEI Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

MEI Pharma, Inc. announced delayed 10-Q filing

We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

MEI Pharma Receives Non-Compliance Notice from Nasdaq

We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate

Recent updates

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data

MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023

MEI Pharma, Inc., Annual General Meeting, Dec 18, 2023

MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

MEI Pharma, Inc. Announces Board Changes

MEI Pharma, Inc. to Report Fiscal Year 2023 Results on Sep 26, 2023

MEI Pharma, Inc. Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN) in Patients with Previously Treated Metastatic Colorectal Cancer

MEI Pharma, Inc. Announces Chief Financial Officer Changes, Effective as of August 1, 2023

MEI Pharma, Inc. Announces Change of CFO, Effective No Later Than September 1, 2023

MEI Pharma, Inc. Announces Executive Changes

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

MEI Pharma, Inc Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Consensus revenue estimates increase by 61%

Price target decreased by 12% to US$2.27

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)

Price target decreased to US$2.90

MEI Pharma, Inc. Initiates Realignment of Its Clinical Development Efforts

Consensus revenue estimates increase by 26%

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)

Price target increased to US$5.83

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MEI Pharma, Inc. Announces Not Stand for Re-Election of Directors

MEI Pharma, Inc., Annual General Meeting, Dec 06, 2022

MEI Pharma, Inc. Announces Not Stand for Re-Election of Cheryl L. Cohen as Member of the Board of Directors

Mei Pharma Announces Changes to Board of Directors

MEI Pharma, Inc. Announces Board Changes

Consensus forecasts updated

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

MEI Pharma, Inc. to Report Fiscal Year 2022 Results on Sep 08, 2022

Price target decreased to US$4.81

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma, Inc. announced delayed 10-Q filing

We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

MEI Pharma Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 11%

Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts

MEI Pharma, Inc. Announces New Key Executive Appointments

No longer forecast to breakeven

MEI Pharma: Another PI3K Delta Progressing To The FDA

Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates

Consensus revenue estimates fall to US$38.1m

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma

Price target increased to US$10.89

Independent Non Executive Director Kevan Clemens has left the company

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.019 loss in 1Q 2021)

We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate

Price target increased to US$11.11

Full year 2021 earnings released: US$0.45 loss per share (vs US$0.51 loss in FY 2020)

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce First Patient Dosed in the Phase 3 Coastal Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-Cell Lymphoma

Forecast to breakeven in 2024

MEI Pharma, Inc.(NasdaqCM:MEIP) dropped from Russell 3000E Value Index

MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program

MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib

MEI Pharma, Inc. and Kyowa Kirin Announce New Clinical Data on Zandelisib At American Society of Clinical Oncology Annual Meeting 2021